Net losses for the company rose due to R&D costs. The post Compass Pathways’ Cash Holdings Grow Despite Heavy Spending on Horizon appeared first...
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED) reported its financial results for the second quarter ending on June 30, 2023. The company has...
Psyence announces a SPAC merger and filing with the SEC for eventual NASDAQ trading. The post Psyence Announces SEC Registration For NASDAQ (by SPAC Merger)...
COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, reported...
TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) — The new U.S. patent application is... The post SciSparc and Clearmind Collaboration Continues to Increase...
Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc.... The post Clearmind Medicine Files Patent Application...
The majority of participants reported significant improvements in their overall mental health The post Psilocybin-like drug may help people suffering...
A study using Compass Pathways’ COMP360 psilocybin compound for anorexia was published in Nature Medicine. The post Positive Results Published for Compass...
Welcome to the News You Might Have Missed, a weekly roundup of psychedelic medicine news to help you catch up and stay informed The post News...
Enveric Biosciences (NASDAQ: ENVB) announced the successful completion of preclinical ADME and toxicology studies for its lead candidate EB-373. EB-373...